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REVIEW
Abstract: Severely septic patients continue to experience excessive morbidity and mortality
despite recent advances in critical care. Although significant resources have been invested in
new treatments, almost all have failed to improve outcomes. An improved understanding of
sepsis pathophysiology, including the complex interactions between inflammatory, coagulation,
and fibrinolytic systems, has accelerated the development of novel treatments. Recombinant
human activated protein C (rhAPC), or drotrecogin alfa (activated) (DAA), is currently the
only US Food and Drug Administration (FDA)-approved medicine for the treatment of severe
sepsis, and only in patients with a high risk of death. This review will discuss the treatment of
severe sepsis, focusing on recent discoveries and unresolved questions about DAA’s optimal
use. Increasing pharmacological experience has generated enthusiasm for investigating
medicines already approved for other indications as treatments for severe sepsis. Replacement
doses of hydrocortisone and vasopressin may reduce mortality and improve hypotension,
respectively, in a subgroup of patients with catecholamine-refractory septic shock. In addition
to discussing these new indications, this review will detail the provocative preliminary data
from four promising treatments, including two novel modalities: antagonizing high mobility
group box protein and inhibiting tissue factor (TF). Observational data from the uncontrolled
administration of heparin or statins in septic patients will also be reviewed.
Keywords: septic shock; drotrecogin alfa, vasopressin, new therapies, statins, high mobility
group box protein
Introduction
Severe sepsis represents one of the most common diagnoses in patients admitted to
the intensive care unit (ICU). This systemic inflammatory response to an infectious
stimulus resulting in organ dysfunction (Bone et al 1992; Levy, Fink, et al 2003)
afflicts more than 750 000 patients (Martin et al 2003) and consumes almost 17 billion
healthcare dollars in the US each year (Angus et al 2001). Although sepsis without
organ dysfunction is a relatively benign condition, severe sepsis results in more than
225 000 deaths in the US annually (Angus et al 2001; Martin et al 2003). Furthermore,
an aging population and growing number of immunosuppressed patients treated in
an environment of emerging antibiotic resistance and expanding use of invasive
procedures will almost assuredly increase the burden of sepsis even further (Martin
et al 2003).
Although patients with the above predispositions experience higher incidences
of sepsis, the syndrome can affect anyone, including previously young, healthy people,
often with devastating consequences (Quartin et al 1997; Weycker et al 2003). Despite
modern advances in critical care, one-third to half of all severely septic patients fail
Todd W Rice
Division of Allergy, Pulmonary, and
Critical Care Medicine, Department
of Medicine, Vanderbilt University
School of Medicine, Nashville, TN,
USA
Correspondence: Todd W Rice
Division of Allergy, Pulmonary, and
Critical Care Medicine, Vanderbilt
University School of Medicine, T-1218
MCN, Nashville, TN 37232-2650, USA
Tel +1 615 322 3412
Fax +1 615 343 7448
Email todd.rice@vanderbilt.edu
Treatment of severe sepsis: where next?
Current and future treatment approaches after
the introduction of drotrecogin alfaVascular Health and Risk Management 2006:2(1) 4
Rice
to survive to hospital discharge (Angus et al 2001; Weycker
et al 2003), and those with septic shock experience even
higher mortality rates (Rangel-Frausto et al 1995).
Furthermore, the detrimental effects of sepsis continue
beyond the acute process. Patients who survive the initial
episode experience higher rates of death for the first year
after hospital discharge compared with disease and age-
matched controls (Weycker et al 2003).
Recent years have seen renewed enthusiasm for novel
sepsis therapies, marked by an increased number of large,
randomized, controlled trials. This review will discuss a few
of the treatment modalities arising from these studies,
including new information about recombinant human
activated protein C (rhAPC), the only pharmaceutical agent
approved by the US Food and Drug Administration (FDA)
for the treatment of severe sepsis and septic shock. Other
advances in the care of patients with septic shock, including
replacement doses of corticosteroids in those with relative
adrenal insufficiency and vasopressin in those with
catecholamine-dependent hypotension, will also be
summarized. This review will also include a discussion of a
few of the provocative pharmaceutical agents with
antiinflammatory and/or anticoagulant properties currently
being investigated for the treatment of septic shock. Other
novel agents and techniques such as macrophage migration
inhibitory factor (MIF), caspase inhibitors, toll-like
receptor 4 inhibitors, lipophilic antiendotoxins, extra-
corporeal techniques such as hemofiltration or adsorption,
and fluid resuscitation strategies, are beyond the scope of
this review and will not be discussed.
Sepsis pathophysiology
The systemic inflammatory response syndrome (SIRS)
consists of many signs and symptoms, including tachypnea
(or hypocapnea), fever, tachycardia, leukocytosis (or
leukopenia), and greater than 10% immature white blood
cells (Bone et al 1992; Levy, Fink, et al 2003). The presence
of these signs early in the course of most septic patients
fueled an initial belief that the disease resulted from an
overwhelming inflammatory response to the underlying
infection. Early studies demonstrated that administering
endotoxin or cytokines such as tumor necrosis factor alpha
(TNF-α) or interleukin-1 (IL-1) to humans resulted in an
identical systemic inflammatory response syndrome with
hypotension, further indicting inflammation in the
pathophysiology.
More recent observations, however, indicate that
coagulopathy also plays a role in sepsis pathophysiology,
with microthrombi in the arterioles and venules of various
organs (Levi et al 1993; Thijs et al 1993). Further
investigations revealed a complex interaction between the
inflammatory and coagulation systems, with inflammation
stimulating procoagulant pathways, inhibiting fibrinolysis,
and down-regulating other mediators controlling coagulation
(van Deventer et al 1990; Esmon et al 1991, Aird 2001;
Hotchkiss and Karl 2003). The resultant procoagulant state
favors the formation of microthrombi in small vessels,
leading to local hypoperfusion and contributing to
subsequent organ dysfunction.
Initial attempts at treating septic patients focused on
inhibiting mediators of the early inflammatory cascade.
Although many were able to alter measures of inflammation,
none were successful in improving clinical outcomes in
septic patients (Zeni et al 1997; van der Poll 2001;
Riedemann et al 2003; Vincent, Sun, et al 2003) (Table 1).
Table 1: Some unsuccessful antiinflammatory treatments for
septic shock in humans. All the listed antiinflammatory
treatments, with the exception of replacement dose
corticosteroids, have failed to demonstrate improvement in
clinical outcomes in patients with septic shock
Treatments directed against:
Endotoxin (Lipopolysaccharide, [LPS])
LPS antisera
Murine antibodies against lipid A component of LPS
Human antibodies against lipid A component of LPS (HA–1A)
Bactericidal/permeability-increasing protein
Arachadonic acid metabolites
Ibuprofen (cyclooxygenase inhibitor)
Prostaglandin E1
Ketoconazole
Early cytokines
Antitumor necrosis factor (TNF) fab dimers
AntiTNF fab monomers
Soluble TNF receptor fusion protein
Murine monoclonal antiTNF antibodies
Interleukin-1 receptor antagonist
Nonspecific antiinflammatory treatments:
High dose corticosteroids
Replacement dose corticosteroids
 a
Intravenous immunoglobulin
Immunonutrition
Platelet activating factor-acetylhydrolase
Tifacogin (recombinant human tissue factor pathway inhibitor)
a Replacement dose corticosteroids, in combination with fludrocortisone,
improved survival in patients with septic shock and relative adrenal
insufficiency, as defined by an inadequate response to corticotropin stimulation
testing (Annane et al 2002).Vascular Health and Risk Management 2006:2(1) 5
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The reasons for these failures are heavily debated, but may
include targeting the wrong inflammatory mediators,
administering the treatment too late in the inflammatory
course, patient heterogeneity, or a limited role for
inflammation in causing organ dysfunction. The advance-
ment of the understanding of sepsis pathophysiology to
include the coagulation system, along with the availability
of new agents possessing both antiinflammatory and
anticoagulant properties, has renewed enthusiasm for
discovering effective treatments for patients afflicted with
sepsis (Matthay 2001). Unfortunately, many therapies
directed against the coagulopathy associated with sepsis
have also demonstrated disappointing results (Table 2).
Activated protein C
The liver, through a vitamin K-dependent pathway,
synthesizes protein C and secretes it into the circulation as
an inactive zymogen. Endothelial protein C receptor
(EPCR), along with thrombin bound to thrombomodulin
locally, facilitates the conversion of protein C to its active
form. Activated protein C (APC) possesses many important
physiological properties, including promoting fibrinolysis
by inhibiting the release of plasminogen activator inhibitor
type 1 (PAI-1) and limiting the generation of thrombin at
the local site of inflammation. Equally important, APC
functions as an anticoagulant by inactivating clotting factors
Va and VIIIa and limits inflammation by inhibiting
thrombin-induced production of inflammatory cytokines
from monocytes (Esmon et al 1991). Furthermore, APC,
via binding with EPCR on endothelial cells, reduces
permeability injury induced by thrombin (Zeng et al 2004;
Finigan et al 2005). Similar binding of APC with EPCR on
epithelial cells and white blood cells reduces apoptosis and
inhibits chemotaxis, respectively (Mosnier and Griffin 2003;
Nick et al 2004; Macias et al 2005). Inflammatory states,
such as septic shock, impair the thrombin-thrombomodulin
complex-mediated activation of Protein C and induce
shedding of EPCR from cell surfaces, which increase the
levels of soluble EPCR and shift the milieu to one of
inflammation and coagulation. This alteration of homeo-
stasis results in microvascular thrombi formation and organ
dysfunction. Furthermore, most patients with severe sepsis
have low levels of the protein C zymogen (Bernard et al
2001), and decreased levels portend worse outcomes (Yan
et al 2001).
In the Protein C Worldwide Evaluation in Severe Sepsis
(PROWESS) trial, administration of exogenous rhAPC, also
known as drotrecogin alfa (activated) (DAA) (Eli Lilly and
Co, Inc, Indianapolis, IN, USA), significantly reduced 28
day, all-cause mortality compared with placebo in septic
patients with at least one organ failure. Enrollment in this
double-blind, placebo-controlled trial was terminated for
efficacy after only 1690 of 2280 planned patients because
the treatment group experienced a 20% relative reduction
and 6% absolute reduction in mortality compared with those
given placebo (24.7% vs 30.8%; p = 0.005). The survival
difference appeared shortly after initiation of the infusion,
increased throughout the 28-day study period (Bernard et
al 2001), and persisted into long-term follow-up (Angus et
al 2003).
Who should receive APC?
Although the FDA used the results from the PROWESS
study to approve DAA in November 2001 as the first drug
indicated for use in severely septic patients, they limited
the indication to those with a high risk of death. When
dividing the enrolled patients by severity of illness scores
(APACHE II [Acute Physiology and Chronic Health
Evaluation II], SOFA [Sequential Organ Failure
Assessment], etc), DAA produced the largest benefit in the
sickest subgroups with an absolute mortality reduction of
13% (relative mortality reduction of 30%; p = 0.0002) in
patients with APACHE II scores totaling more than 24 and
7.4% (relative reduction of 19%) in patients with more than
one organ dysfunction (Bernard 2003). Although not
required for entry into the study, 88% of patients enrolled
in the PROWESS study possessed baseline cardiovascular
dysfunction, or septic shock, with 75% having sepsis-
Table 2: Elements of the coagulation homeostasis targeted
as treatment for humans with septic shock. The only agent
targeting coagulation homeostasis that has demonstrated a
reduction in mortality to date is drotrecogin alfa (activated),
which reduced 28-day all-cause mortality in patients with at
least one organ dysfunction attributable to sepsis (Bernard et
al 2001)
Platelets:
Platelet activating factor receptor antagonist
Platelet activating factor-acetylhydrolase
Protein C:
Drotrecogin alfa (activated) (Recombinant human activated
protein C)
Tissue factor
Tifacogin (recombinant human tissue factor pathway inhibitor)
Antithrombin III
High dose antithrombin IIIVascular Health and Risk Management 2006:2(1) 6
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induced dysfunction of at least two organ systems. The
relatively limited number of patients with less severe sepsis
made it difficult to reach conclusions about the effects of
DAA in such patients. A subsequent trial was undertaken to
evaluate the effect of rhAPC on these septic patients with
only a single organ dysfunction. The Administration of
Drotrecogin Alfa (activated) in Early Severe Sepsis
(ADDRESS) trial was stopped after an interim analysis of
an initial 2640 of the 11 000 targeted patients due to a low
likelihood of demonstrating a significant mortality benefit
for such low risk patients (Abraham et al 2005). The recently
published data demonstrated similar 28-day (18.5% vs 17%;
p = 0.38) and in-hospital (20.6% vs 20.5%) all-cause
mortality rates for patients treated with either rhAPC
compared with placebo. Similarly, a randomized, double-
blind, placebo controlled study of drotrecogin alfa
(activated) in children with severe sepsis was also terminated
early after 400 patients as the data safety and monitoring
board concluded DAA was highly unlikely to show
improvement in time to resolution of organ failure compared
with placebo (DHP 2005). All-cause, 28-day mortality rates,
although slightly lower than those seen in adults enrolled in
the PROWESS and ADDRESS trials, also did not differ
between treatment groups (17% vs 18%).
The subgroups of septic patients for which DAA
treatment is the most beneficial continues to be hotly debated
(Ely et al 2002; Warren et al 2002). In the PROWESS trial,
rhAPC decreased mortality rates compared with placebo
consistently across all demographic subgroups defined by
age, sex, and race (Bernard et al 2001; Bernard 2003), as
well as across different underlying disease states including
cancer, chronic obstructive pulmonary disease, and
preexisting congestive heart failure (Bernard et al 2001).
Futhermore, DAA treatment resulted in a consistent
reduction in mortality for different types (gram-positive,
gram-negative, mixed, or fungus), and sites of infection
(Bernard et al 2001), with the exception of urinary tract
infections, where limited data prevented definitive
conclusions. Only 27% of patients enrolled in the
PROWESS trial were postoperative from either elective or
emergency surgery, which limits conclusions about the
efficacy of DAA in these patients. Considerably more
postoperative patients (n = 1002) were enrolled in the
ADDRESS trial, which demonstrated that postoperative
patients with only a single organ dysfunction experienced
significantly higher 28-day mortality rates (20.7% vs 14.1%;
p = 0.03) and numerically higher in-hospital mortality rates
when administered DAA compared with those given placebo
(23.4% vs 19.7%; p = 0.26) (Abraham et al 2005). Although
the primary cause of death in this population was sepsis-
related, postoperative patients treated with rhAPC
experienced significantly more bleeding events than those
treated with placebo. Of the surgical patients who had a
bleeding episode, more patients treated with rhAPC than
placebo died of sepsis-induced multiorgan dysfunction or
hemorrhage (Abraham et al 2005).
Aside from severity of illness, measured by number of
organ failures, identifying baseline prognostic indicators has
proven difficult. Data from over 1000 severely septic patients
receiving placebo in multiple, randomized, phase III trials
demonstrated that patients who either develop new or fail
to improve existing organ dysfunctions over the initial
24 hours of severe sepsis experience significantly higher
morbidity and mortality, even after correcting for severity
of illness (Levy, Macias, et al 2003; Vincent, Sundin, et al
2003). Although the development of septic shock and
cardiovascular collapse is frequently recognized as a poor
prognostic indicator, evidence now establishes that failing
to improve or worsening shock over the same time period
also confers significant mortality. Unfortunately, it remains
problematic to determine which patients are likely to
improve over the first 24 hours. Additional indicators of
outcome will become more clear as investigations into
prognostic factors such as B-type natriuretic peptide (BNP)
and procalcitonin continue. Numerous studies have
demonstrated that elevated levels of procalcitonin are a
sensitive marker for sepsis (Assicot et al 1993; Ugarte et al
1999; Aikawa et al 2005), and that higher levels portend
worse prognosis (Clec’h et al 2004). Likewise, higher levels
of BNP in patients with septic shock have also been shown
to correlate with worse outcomes (Witthaut et al 2003;
Brueckmann et al 2005). Furthermore, treatment with
rhAPC lowered BNP levels and was associated with
improved outcomes (Brueckmann et al 2005). Future studies
will need to be undertaken to determine if these, or other
similar sepsis markers, can be used to direct sepsis therapies
to those patients most likely to benefit or if these markers
can be used to evaluate effectiveness of treatment.
Timing of APC administration
Early treatment of septic shock is vitally important for
minimizing morbidity and mortality. For many years,
cardiologists and neurologists have emphasized that “time
is heart” and “time is brain” in the treatment of myocardialVascular Health and Risk Management 2006:2(1) 7
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infarction and stroke, respectively. In patients with severe
sepsis, “time is tissue.” Rivers et al (2001) demonstrated
that goal-directed resuscitation in the initial 6 hours of septic
shock reduced 28-day, all-cause mortality. Goal-directed
resuscitation did not decrease mortality during the 6 hour
resuscitation period, but patients who received this therapy
experienced considerably less sudden cardiac death in the
days after the resuscitation period. Likewise, evidence
suggests that early administration of appropriate antibiotics
reduces mortality in septic patients (Ibrahim et al 2000).
Similar administration timing data have been
accumulated for rhAPC. Post-marketing analysis of patients
receiving DAA provides evidence that administration within
24 hours of initial organ dysfunction decreases mortality.
In a retrospective review of rhAPC-treated patients from 5
academic medical centers, early administration of DAA was
associated with reduced mortality (Odds Ratio [OR] 0.52;
95% Confidence Interval [CI]: 0.45–0.60), even after
controlling for age, other organ dysfunctions, mechanical
ventilation, and vasopressor use (Wheeler, Steingrub, et al
2003). In the PROWESS trial, the majority of patients
received rhAPC within 24 hours of meeting severe sepsis
criteria, with a 17–18 hour average time to initiation of DAA
(Bernard et al 2001). However, retrospective analysis
demonstrates that post-marketing administration occurs
significantly later in the disease course, starting an average
of 2.3 days after the onset of severe sepsis (Schmidt et al
2003). Earlier administration improved outcome, with 33%
mortality in patients beginning the infusion on the same
day they developed their initial sepsis-related organ
dysfunction, compared with 40% in those commencing the
day after, and 52% in patients starting after the second day
of organ dysfunction (p = 0.05) (Wheeler, Steingrub, et al
2003). Furthermore, a prospective, phase IIIb study of 2378
patients treated with DAA found mortality rates of 33%
when DAA was initiated on the same calendar day as
developing severe sepsis compared with 41% for those
treated after the first day (p = 0.02) (Wheeler, Doig, et al
2003). Regression analysis, using an integrated database of
over 4400 patients treated with either rhAPC or placebo up
to 72 hours after the development of organ dysfunction from
5 separate severe sepsis studies, found a relative risk of death
for patients treated at the onset of organ dysfunction of 0.67,
compared with 0.76 and 0.88 for those treated 12 and 24
hours later, respectively (Vincent, Sundin, et al 2003). The
time from development of organ dysfunction to treatment
with DAA in the recently stopped ADDRESS trial averaged
48 hours, which caused many to speculate that delayed
treatment reduces effectiveness (Abraham et al 2005).
Whether a time point exists in the course of severe sepsis
after which DAA is no longer effective remains unknown.
However, administration early in the course clearly improves
survival, and delaying administration, even by as little as a
few hours, increases mortality.
Likewise, it remains unknown whether longer treatment
would benefit subgroups of severely septic patients.
Although rhAPC was administered for a total of 96 hours
in the PROWESS study, many physicians believe that
extended treatment is warranted for patients who continue
to manifest organ dysfunction. An ongoing study (EXTEND
[A Phase IIIb Study to Determine Efficacy and Safety of
Extended Drotrecogin Alfa (Activated) Therapy in Patients
With Persistent Requirement for Vasopressor Support After
96 Hour Infusion With Commercial Drotrecogin Alfa
(Activated)]) is investigating whether continuation of DAA
longer than 96 hours is beneficial in septic shock patients
with continued cardiovascular compromise.
APC and bleeding
Treatment with rhAPC is not without risk. Despite excluding
patients at high risk of bleeding (ie, multiple traumatic
injuries, initial platelet count below 30 000/mL, liver failure)
from enrollment in both the PROWESS and ADDRESS
trials, treatment with DAA increased the risk of bleeding
compared with placebo. The incidence of serious bleeding,
defined as any intracranial hemorrhage, life-threatening
bleed, or blood loss requiring transfusion of more than
3 units of packed red blood cells on 2 consecutive days,
was almost twice as high when DAA was administered
(3.5% vs 2.0% in PROWESS; p = 0.06; and 3.9% vs 2.2%
in ADDRESS; p = 0.01) (Bernard et al 2001; Abraham et al
2005). Patients with either traumatic injuries of highly
vascular organs or blood vessels, markedly abnormal
pretreatment coagulation parameters, or ulcerations of the
gastrointestinal tract, experienced most of the serious
bleeding episodes (Bernard et al 2001, 2003). Not
surprisingly, these bleeding rates compare similarly with
those seen with other forms of full-dose, systemic
anticoagulation, such as unfractionated or low-molecular
weight heparin for the treatment of pulmonary embolus or
myocardial infarction (Dolovich et al 2000). In addition,
serious bleeding rates did not increase when subcutaneous
low-molecular-weight or unfractionated heparin (up to
15 000 units per day) were administered concomitantly withVascular Health and Risk Management 2006:2(1) 8
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rhAPC to prevent deep vein thromboses (3.7% with
heparin vs 3.5% without) (Bernard et al 2001). The risk of
bleeding when rhAPC is administered concomitantly with
prophylactic unfractionated and low-molecular-weight
heparin is being further evaluated in an ongoing prospective,
randomized study (Lilly EVBR Study). The increased risk
of severe bleeding was found to be limited to the peri-
infusion period (ie, duration of the infusion plus an
additional 24 hours). Upon completion of the infusion,
bleeding rates in patients treated with DAA were identical
to those given placebo (Siegel 2002). Fortunately, rhAPC
is rapidly degraded by serum proteases, yielding a half-life
of minutes, regardless of renal or hepatic function. This
allows many of these bleeding episodes to be effectively
managed by merely discontinuing the infusion.
Particular concern has arisen over the risk of intracranial
hemorrhage with the use of APC. Analysis of almost 3000
patients treated with rhAPC, including those in open-label
trials, found the incidence to be 0.6%, with most events
occurring in patients suffering meningitis, platelet counts
less than 30 000/µL, or both (Ely et al 2002; Bernard et al
2003). Less severely ill patients experienced similar rates
of CNS bleeding in the ADDRESS trial (0.5% DAA vs 0.4%
placebo) (Abraham et al 2005). Unfortunately, CNS
bleeding may occur more frequently in children treated with
DAA. In the randomized, placebo-controlled trial of severely
septic children, 4 patients (2%) treated with DAA had CNS
hemorrhages compared with 1 (0.5%) in the placebo arm.
Three of the 4 intracranial bleeds associated with DAA
treatment occurred in children less than 60 days old (DHP
2005).
Promising treatments for the
future of septic shock:
anticoagulants with
antiinflammatory properties
Recent advances in the complex pathophysiology of sepsis
have illuminated the delicate homeostasis in which the
inflammatory and coagulation systems coexist. The
overwhelming early inflammation during septic shock alters
this tenuous balance and initiates a cascade of events that
result in a highly proinflammatory and procoagulant
environment. In this environment, inflammation and
coagulation act in concert and augment each other, with
both playing a role in the morbidity and mortality associated
with septic shock. The recently discovered success of APC,
with its ability to interrupt both the inflammatory and
coagulation cascades simultaneously, has spurred further
investigations into additional agents, which similarly possess
both antiinflammatory and anticoagulant properties.
Heparin
Heparin binds antithrombin III to form a complex capable
of inhibiting thrombin. This inhibition helps prevent clot
formation, and has allowed glycosaminoglycan to be utilized
clinically as an anticoagulant for more than 60 years. More
recent data, however, demonstrate that heparin also
possesses antiinflammatory properties. P- and L-selectins
are expressed locally at inflammation sites. These
endothelial cell surface markers play an important role in
attracting leukocytes and allowing them to infiltrate into
the inflamed tissue. Heparin, by blocking these P- and L-
selectins, impedes leukocyte adhesion to the endothelium
and prevents infiltration into tissue (Want et al 2002). In
addition, heparin inhibits TNF-α, a key component in the
inflammatory cascade. Heparin also inhibits complement
activation and platelet activating factor, two mediators that
propagate the proinflammatory and procoagulant cycle of
septic shock (Tyrell et al 1999). Since the only approved
treatment for septic shock, namely APC, possesses both
antiinflammatory and anticoagulant properties, many have
hypothesized that heparin might also be effective in the
treatment of sepsis and at a considerably lower cost
compared with novel medicines.
The use of heparin to prevent deep vein thrombosis in
patients with severe sepsis randomized to receive placebo
in therapeutic trials of other agents provides some prelimi-
nary data on its possible efficacy in these patients. Patients
who received prophylactic dosages of unfractionated or low-
molecular weight heparin experienced reduced mortality
rates compared with patients given placebo without heparin
(Davidson et al 2002; Langer et al 2002). This association,
however, must be interpreted with caution due to the
possibility of indication bias. In other words, the decision
to administer heparin to these patients is left to the discretion
of the treating medical team and not randomized. Other
clinical considerations, such as the presence or absence of
disseminated intravascular coagulation or increased bleeding
risk, strongly influence the clinicians’ decision to prescribe
heparin. As such, patients with severe sepsis who are chosen
to receive heparin prophylaxis are almost assuredly different
than those not chosen to receive it.
Unfortunately, quality data on the effectiveness of
heparin in the treatment of severe sepsis are sparse. Even
data on its effectiveness in animal models of severe sepsisVascular Health and Risk Management 2006:2(1) 9
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or septic shock are lacking. Furthermore, preclinical data
on the optimal dose, timing, and duration of treatment is
similarly unavailable and randomized or placebo-controlled
studies in humans have not been conducted. With its known
significant risks of hemorrhage and heparin-induced
thrombocytopenia, the paucity of animal and early clinical
data will need to be overcome prior to advancing to large,
definitive studies in severely septic humans. Until additional
data is generated, including that from randomized controlled
trials in humans, the effectiveness and safety of heparin in
treating severe sepsis will remain unknown.
Tissue factor inhibitors
Tissue factor (TF) is an important transmembrane
glycoprotein mediator of both the coagulation and
inflammatory cascades. Normally, TF is expressed in the
subendothelial cells of the vascular adventitia (Eilertsen and
Osterud 2004). In this location, TF is protected from
exposure to the systemic circulation (Morrissey et al 1993).
Proinflammatory cytokines, such as TNF- and IL-1, induce
endothelial cells to express TF (Meszaros et al 1994). When
expressed on endothelial cells, TF is exposed to the
circulation where it can bind with circulating activated factor
VII and initiate the coagulation cascade (Osterud and
Rapaport 1977). Likewise, coagulation factors generated by
TF-initiated coagulation, like activated factor VII, activated
factor X, and thrombin, elicit inflammatory responses by
attracting neutrophils and stimulating the release of
cytokines from macrophages and endothelial cells (Esmon
et al 1991). Localized activation of the coagulation cascade
associated with inflammation helps control the spread of
infectious agents. In severe sepsis, however, TF expression
often spreads beyond the local site of inflammation, resulting
in a diffuse, prothrombotic state similar to disseminated
intravascular coagulopathy (Cressey 2000). This coagulo-
pathic state further propagates inflammation (Warr et al
1990). The end result is an accelerated cycle of coagulation
and inflammation that results in endothelial dysfunction and
end-organ damage.
Antagonism of TF, either through TF pathway inhibitor
(TFPI) (Creasey et al 1993) or anti-TF antibodies (Taylor
et al 1991) in nonhuman primate models of sepsis, reduces
both inflammation and coagulation and improves mortality.
TFPI is a naturally occurring protein that functions in
maintaining coagulation homeostasis. Like heparin, TFPI
possesses both anticoagulant and antiinflammatory
properties. In its active, untruncated form, TFPI inhibits TF
and decreases the formation of thrombin. TFPI is truncated,
however, in many procoagulant states, such as sepsis.
This truncation decreases its anticoagulant activity
(Wesselschmidt 1993), which ultimately shifts homeostasis
towards coagulation, predisposing patients to form
microthrombi.
Many experts enthusiastically embraced the concept of
inhibiting TF, either through TFPI or anti-TF antibodies, as
a means of treating severe sepsis, because of the dual role
that TF plays in accelerating both inflammation and
coagulation. Unfortunately, the recently completed multi-
center, randomized, blinded phase 3 trial of recombinant
exogenous TFPI demonstrated no mortality benefit in
severely septic patients (n = 880) compared with placebo
(n = 874) (Abraham et al 2003). Although the overall results
were discouraging, a closer look at the study data has
renewed enthusiasm for TF antagonism. In the early phase
of the trial, prior to large changes in mortality rates, the
data suggested a benefit from TFPI administration.
Furthermore, TFPI appeared to decrease mortality in the
subgroup of patients with normal international normalized
ratios (INR) < 1.2. Consequently, further studies investi-
gating the effectiveness of TFPI in subgroups of patients
with severe sepsis are planned. In addition, investigations
into the safety and effectiveness of anti-TF antibodies in
treating patients with severe sepsis and pulmonary
dysfunction are currently in the early stages of clinical trials.
Treatments for subgroups of
patients with septic shock
Vasopressin or antidiuretic hormone
Vasopressin, a protein produced in the hypothalamus (Swaab
et al 1975), stored in the posterior pituitary, and released
into the circulation in response to many complex stimuli
(Schrier et al 1979; Wood and Chen 1989), produces a wide
range of physiologic effects, including maintaining blood
pressure homeostasis (Reid and Schwartz 1984). Also
known as antidiuretic hormone (ADH), vasopressin restores
vascular tone in patients with distributory shock via a
number of mechanisms. Acting through vascular
V1-receptors, the endogenous hormone directly induces
vasoconstriction (Reid and Schwartz 1984). In addition,
ADH also modulates potassium-adenosine triphosphate
(ATP) channels and nitric oxide synthesis. Furthermore,
vasopressin potentiates the adrenergic effects of other
vasoconstrictor agents (Landry and Oliver 2001). Although
vital in elevating low blood pressure, especially when it is
the result of inappropriate vasodilation, vasopressin doesVascular Health and Risk Management 2006:2(1) 10
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not significantly alter vascular smooth muscle constriction
in humans with normal blood pressure (Graybiel and Glendy
1941; Wagner and Braunwald 1956; Schwartz et al 1983).
Vasopressin also has varying effects in different tissues. In
nonvital arterial systems which feed skeletal muscles, fat,
and skin, vasopressin results in potent vasoconstriction, but
causes considerably less vasoconstriction in the coronary,
mesenteric, and cerebral circulations (Laszlo et al 1991).
Kinetics of serum vasopressin levels in
septic shock patients
Hypotension, hypovolemia, and elevated serum osmolality
are the most potent stimuli for the release of vasopressin
from the posterior pituitary (Schrier et al 1979; Quail et al
1987; Norsk et al 1993). Despite the potency of the stimulus,
only 10%–20% of the vasopressin stored in the posterior
pituitary is available for immediate release. Subsequent
release of vasopressin occurs at a much slower rate, resulting
in a biphasic response (Holmes, Patel, et al 2001; Sharshar
et al 2003). In the early phase of distributive states, such as
septic shock, serum ADH levels rise appropriately as the
posterior pituitary rapidly secretes the 10%–20% of its
available stores to maintain organ perfusion. As vaso-
dilatation continues, serum concentrations begin to fall,
ultimately leading to inadequate levels of vasopressin within
36 hours in patients with persistent vasodilatation and
distributive shock (Sharshar et al 2003). Although the exact
mechanism for these falling levels remains an enigma, it
appears to occur through decreased hypothalamic
production and/or release of pituitary stores and not via
increased catabolism, as levels increase appropriately when
exogenous vasopressin is given (Bourque and Oliet 1997).
Although vasopressin has relatively little effect on blood
pressure in humans without hypotension, low blood pressure
from vasodilatation results in an increased sensitivity to the
vasoconstrictive effects of vasopressin (Landry et al 1997a).
Consequently, its administration in relatively low
replacement doses in this condition significantly increases
arterial blood pressure. Unfortunately, the optimal dose of
vasopressin for treatment of septic shock remains unknown.
In animal models, limited data suggest that continuous
infusion of low doses produces vasoconstriction only in
selective arterial systems, with carotid blood flow actually
increasing without compromising blood flow to other vital
organs (Malay et al 2004). Moderately higher doses likely
result in more potent vasoconstriction in arterial vascular
beds and may induce mesenteric, renal, or coronary
ischemia. Two recent human studies have demonstrated
increased gastric regional production of carbon dioxide upon
administration of vasopressin, suggesting compromised gut
blood flow (Klinzing et al 2003; van Haren et al 2003). The
combination of the animal and human data has led many
experts to recommend a continuous infusion of vasopressin
only as a supplement to other vasoactive agents and at a
low dose (0.01–0.04 Units/minute [U/min]) without titrating
higher if blood pressure remains inadequate (Dellinger et
al 2004; Malay et al 2004; Holmes and Walley 2004).
Clinical studies of vasopressin in septic shock
Landry and colleagues (1997b) found markedly lower serum
vasopressin in patients with established septic shock
requiring catecholamines compared with those with
cardiogenic shock needing catecholamines (3.1 pg/mL vs
22.7 pg/mL, p < 0.001). They then supplemented the
inadequate endogenous levels with low, physiologic doses
of exogenous vasopressin in these septic shock patients and
discovered a significant improvement in arterial blood
pressure, further confirming the contributory role of
inadequate vasopressin levels to this state of distributive
shock. Exogenous supplementation of vasopressin in these
patients produced a marked increase in systemic vascular
resistance and a slight decrease in cardiac output, which
suggests vasoconstriction as the mechanism of increasing
arterial blood pressure. Subsequent studies have confirmed
the association of inadequate levels of vasopressin with
vasodilatory shock (Argenziano et al 1997, 1998; Sharshar
et al 2003).
Although numerous studies have investigated sup-
plementing inadequate endogenous levels with relatively low
doses (0.01–0.1 U/min) of exogenous vasopressin in patients
with catecholamine-dependent septic shock, most have done
so through open-labeled use of the drug (Table 3).
Furthermore, these studies fail to evaluate the effect of these
replacement doses of vasopressin on clinically important
outcomes such as mortality, renal failure, or ICU, or hospital
length of stay. Instead, the studies utilize surrogate endpoints
as evidence of efficacy such as increased blood pressure,
increased peripheral vascular resistance, and decreased or
abolished need for catecholamine support.
Vasopressin may possess other beneficial effects in
patients with septic shock. Prospective open-labeled studies
have demonstrated increased urine output with exogenous
vasopressin administration (Landry et al 1997a; Tsuneyoshi
et al 2001), supporting the findings of a few retrospective
studies (Gold et al 2000a, 2000b; Holmes, Walley, et al
2001). Unfortunately, the mechanism of this increased urineVascular Health and Risk Management 2006:2(1) 11
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flow remains ill-defined and may simply be the result of
improved renal perfusion through increased arterial blood
pressure.
Only a limited number of prospective, randomized,
blinded studies have compared the effects of vasopressin
supplementation with either placebo or another vasopressor
(Argenziano et al 1997; Malay et al 1999; Patel et al 2002).
Although these studies provide objective evidence that
vasopressin can improve short-term surrogate outcomes such
as increasing mean arterial pressure or reducing
catecholamine doses, data that vasopressin administration
improves patient mortality, intensive care, or hospital lengths
of stay, or other long-term clinical outcomes, is still lacking.
A large, multicenter, randomized, double-blinded, placebo-
controlled Vasopressin and Septic Shock Trial (VASST) is
currently underway to compare the effects of vasopressin
on long-term clinical outcomes, including mortality, renal
function, and lengths of stay in patients with catecholamine-
dependent septic shock (Cooper et al 2003). Until data from
this study are available, vasopressin should probably
continue to be reserved as a “rescue” vasopressor agent to
be given in low, physiologic doses (0.04 U/min) only to
patients unable to maintain an adequate blood pressure
despite the use of continuous catecholamine support.
Corticosteroid replacement therapy
The antiinflammatory properties of corticosteroids include
inhibition of proinflammatory cytokine production,
enhancement of antiinflammatory mediator release, and
reduction in both the function and migration of inflammatory
cells, such as lymphocytes, monocytes, neutrophils,
macrophages, and eosinophils. Because of these numerous
antiinflammatory effects, many investigators labeled
corticosteroids as the ideal antidote for the presumptive
overwhelming inflammatory response in sepsis.
Unfortunately, high dose corticosteroids administered to
septic patients repeatedly failed to demonstrate clinical
benefit. Furthermore, meta-analyses confirmed the lack of
Table 3: Studies of vasopressin in humans with septic shock. A conglomeration of studies investigating the effects of vasopressin
(antidiuretic hormone; [ADH]) in humans with septic shock
Number Vasopressin
Patient  of  Dose
Reference Design Population/disease patients Comparison Units/minutes Outcomes
Landry et al Prospective, open-label, Septic shock on 10 Pre- vs Post-ADH 0.04 U/min ↑ BP
1997b unrandomized catecholamines
Landry et al Prospective, open-label, Septic shock on 6 Pre- vs Post-ADH 0.01 U/min ↑ BP
1997b unrandomized catecholamines
Landry et al Prospective, open-label, Septic shock on 6 On ADH vs 0.01 U/min ↓ BP on removal
1997b unrandomized, removal catecholamines Post-stopping ADH of ADH
of ADH
Landry et al Prospective, open-label, Septic shock on 5 Pre- vs Post-ADH 0.03–0.04 U/min ↑ BP, ↓ Cat, ↑ UO
1997a unrandomized case catecholamines
reports
Malay et al Prospective, randomized, Trauma patients with 10 ADH (n = 5) vs 0.04 U/min ↑ BP, ↓ NE
1999 placebo-controlled, septic shock on Placebo (n = 5)
double-blinded catecholamines
Dunser et al Retrospective Septic (n = 35) or post- 60 Pre- vs Post-ADH 0.07–0.1 U/min ↑ BP,  ↓ NE, ↓ HR,
2001 cardiotomy shock (n = 25) ↓ CI, ↓ mean PAP,
on catecholamines ↑ liver enzymes,
↓ plt
Holmes, Walley, Retrospective Septic shock on 50 Pre- vs 0.01–0.6 U/min ↑ BP, ↓ Cat, 
et al 2001 catecholamines Post-ADH (avg. 0.5 U/min) ↑UO, ↓ CI
Tsuneyoshi Prospective, open-label Septic shock on 16 Pre- vs Post-ADH 0.04 U/min ↑ BP, ↑ UO
et al 2001 catecholamines
Patel et al 2002  Prospective, randomized, Septic shock 24 ADH (n = 13) vs 0.01 U/min titrated ↑ BP,  ↓ NE,
blinded NE (n = 11)  up to 0.08 U/min ↑ UO, ↑ CCl
Dunser et al Prospective, randomized, Cardiopulmonary 48 NE + ADH (n = 24) vs 0.067 U/min ↑ BP 
2003 blinded bypass ± septic shock NE alone (n = 24) ↓ tachyarrhythmias
Abbreviations: ADH, antidiuretic hormone; BP, blood pressure; Cat, catecholamines; CCl, creatinine clearance; CI, cardiac index; HR, heart rate; NE, norepinephrine;
PAP, pulmonary artery pressure; plt, platelets; PVR, peripheral vascular resistance; SVR, systemic vascular resistance; U/min, units/minute; UO, urinary output.Vascular Health and Risk Management 2006:2(1) 12
Rice
efficacy and even suggested a trend toward harm (Cronin et
al 1995; Lefering and Neugebauer 1995; Zeni et al 1997).
Recent data demonstrate that lower doses of cortico-
steroids, administered over a longer period of time, may
benefit at least one subset of patients with septic shock.
Many patients with refractory septic shock have relative
adrenal insufficiency, lacking adequate adrenal function to
produce an appropriate cortisol response for their level of
illness (Annane et al 2000). Current data now suggest that
moderate doses of corticosteroids, considerably smaller than
those previously found to be ineffective, may prove
beneficial in these septic shock patients with relative adrenal
insufficiency.
A recent double-blinded, multicenter trial randomized
299 French patients with septic shock of less than 8 hours
duration to receive 7 days of either placebo or 50 mg of
intravenous hydrocortisone every 6 hours plus 50 mg of
fludrocortisone via nasogastric tube each day (Annane et al
2002). Although corticotropin stimulation tests were
performed in all patients prior to administration of study
medications, the test results remained unknown to the
investigators and treating physicians until completion of the
study. Administration of replacement dose corticosteroids
improved refractory hypotension and decreased absolute
mortality by 10% as compared with placebo (63% vs 73%
mortality; p = 0.02), but only in the subgroup of septic shock
patients found to have relative adrenal insufficiency. For
the purposes of this study, relative adrenal insufficiency (or
“nonresponders”) was defined by a failure to increase serum
cortisol levels by greater than 9 mcg/dL within 2 hours of
the corticotropin stimulation test (Annane et al 2002).
Unfortunately, only the “nonresponding” subgroup
demonstrated benefit. In fact, for the relatively small subset
of septic shock patients classified as “responders”, or those
who increased their serum cortisol concentrations by greater
than 9 mcg/dL in response to adrenocorticotropin hormone,
treatment with even these moderate replacement doses of
corticosteroids produced a trend toward increased mortality
(53% vs 61%) (Annane et al 2002). This has led many
physicians to perform a cortisol stimulation test in septic
shock patients and immediately initiate steroid replacement
therapy while awaiting the results. If the patient is found to
have an inadequate cortisol response, steroids are continued,
and if the cortisol level rises appropriately, the steroids are
discontinued (Dellinger et al 2004).
Other recently completed studies have shown similar
improvements in hypotension and mortality in septic shock
patients treated with more moderate corticosteroid dosages
(Bollaert et al 1998; Briegel et al 1999), suggesting that at
least some subgroups of septic patients benefit from these
lower and more prolonged doses of corticosteroids. Debate
continues over the exact definition of adrenal dysfunction,
the length of steroid treatment after resolution of shock,
whether steroids should be tapered, and the need for
fludrocortisone as part of the treatment (Cooper and Stewart
2003). Hopefully, the ongoing multicenter, international
CORTICUS (Corticosteroid Therapy of Septic Shock Trial)
study, which randomizes catecholamine-dependent septic
shock patients to replacement dose steroids or placebo until
resolution of shock, will help clarify many of these issues
(Annane et al 2003).
Promising treatments for the
future of septic shock:
antiinflammatory agents
Despite an improved understanding of the delicate
homeostasis between the inflammatory and coagulation
systems, evidence suggests that the cascade of events in
sepsis is initiated by a release of inflammatory mediators.
These mediators result in the clinical signs and symptoms
of sepsis. If allowed to propogate without close regulation,
these mediators contribute to tissue damage. Consequently,
even in the face of numerous previously unsuccessful phase
III trials in humans, inhibiting the initial inflammatory
reaction continues to be a focus of new pharmaceutical
development.
High-mobility group box 1 protein
Despite promising animal and phase II data, treatments
directed against early mediators of inflammation, such as
TNF, IL-1 receptor, or endotoxin (lipopolysaccharide [LPS])
have failed to demonstrate benefit in improving clinical
outcomes in patients with severe sepsis or septic shock
(Table 1). Many experts surmise that initiation of these
agents occurred too late in the inflammatory course to inhibit
its numerous effects, leading to the disappointing results.
Unfortunately, most patients do not present to a medical
care facility until they experience the signs or symptoms
associated with sepsis. Since the inflammatory reaction is
responsible for producing these early symptoms, the
detrimental inflammatory cascade is already well underway
at the time of presentation. Furthermore, many deaths from
sepsis occur later in the course, at least 48–72 hours after
the onset of symptoms, prompting many to speculate that
therapy directed against inflammatory mediators withVascular Health and Risk Management 2006:2(1) 13
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prolonged actions or which appear later in the course might
prove more successful.
High-mobility group box protein 1 (HMGB1) may
represent one such late mediator. This 30 kDa protein was
purified along with histones from nuclei almost three
decades ago (Goodwin and Jones 1977). Named for their
rapid migration on electrophoretic gels, high mobility group
nuclear proteins have been classified as nonhistone
chromatin-associated proteins. The nuclear binding
properties of HMGB1, along with its critical role in gene
transcription, DNA repair and replication have been
extensively studied since its discovery (Einck and Bustin
1985; Bianchi and Beltrame 1988; Bianchi et al 1989).
Recent data suggest that HMGB1 also possesses
inflammatory properties (Andersson et al 2000). Although
it was discovered because of its association with chromatin,
HMGB1 only binds DNA nonspecifically and with low
affinity, allowing movement from the nucleus to the cytosol
through nuclear pores (Falciola et al 1997). Acetylation in
the cytosol prevents nuclear re-entry and allows for
extracellular secretion (Bonaldi et al 2003). Cultured
macrophages secrete HMGB1, in the absence of cell death,
in response to stimulation from LPS, gamma interferon, or
TNF (Wang et al 1999; Andersson et al 2000; Rendon-
Mitchell et al 2003; Chen et al 2004). In addition, HMGB1
is passively released from all nucleated cells upon cell
necrosis, but not apoptosis (Scaffidi et al 2002; Harris and
Andersson 2004).
Once extracellular, HMGB1 functions as an important
inflammatory mediator. Extracellular HMGB1 fuels
inflammation by stimulating the release of additional
proinflammatory cytokines from endothelial cells and
monocytes, including TNF-α, IL-1, IL-6, IL-8, and
macrophage inflammatory protein. Furthermore, HMGB1
also helps regulate coagulation by inducing the expression
of adhesion molecules in endothelial cells, resulting in the
secretion of plasminogen activator inhibitor-1 and tissue
plasminogen activator (Fiuza et al 2003; Treutiger et al
2003). Mice develop markedly elevated levels of serum
HMGB1 when administered LPS (Wang et al 1999; Yang et
al 2004). However, unlike many classic inflammatory
mediators that peak early in the course of sepsis and become
undetectable within a few hours, serum levels of HMGB1
remain undetectable until 8 hours after the onset of sepsis
and continue to increase until reaching a plateau at 24 to
32 hours after sepsis onset (Wang et al 1999; Sunden-
Cullberg et al 2005). Administration of recombinant
HMGB1 provides further evidence for its role in sepsis. Mice
treated with sublethal doses of HMGB1 develop signs of
endotoxemia within 2 hours (Wang et al 1999). Higher doses
result in death at 18–36 hours, even in mice resistant to the
effects of LPS, indicating that HMGB1 is toxic even in the
absence of other mediators of LPS-induced inflammation
(Wang et al 1999). Intratracheal administration of HMGB1
in mice produces neutrophilic lung infiltration and edema,
an alveolitis picture consistent with the acute lung injury
seen in severe sepsis, within about 8 hours and continuing
through 24 hours (Abraham et al 2000).
Patients with severe sepsis and septic shock also have
elevated serum levels of HMGB1 compared with
undetectable levels in healthy controls (Wang et al 1999;
Sunden-Cullberg et al 2005). These elevated levels arise
from both discharge from necrotic cells along with the
production and release of HMGB1 from macrophages,
stimulated by exogenous bacterial LPS and endogenous
proinflammatory cytokines. In addition, one study found a
prognostic implication for serum HMGB1 levels, as
nonsurviving septic patients demonstrated considerably
higher levels than those who survived to hospital discharge
(Wang et al 1999). A recent study has also confirmed the
presence of elevated levels of HMGB1 in plasma and
bronchoalveolar lavage in septic patients with acute lung
injury (Yang et al 2004). Although HMGB1 was present in
similarly low levels in bronchoalveolar lavage fluid from
healthy adults and at the onset of disease in those with sepsis,
peak levels were 2–4 times higher during the course of lung
injury.
Blocking the effects of HMGB1, even well after signs
of sepsis develop, improves survival in multiple animal
models (Ulloa et al 2002; Yang et al 2004). Anti-HMGB1
antibodies, when given both before and after LPS
instillation, protect mice from the lethal effects of endotoxin
(Wang et al 1999). Importantly, treatment with these
antibodies did not just extend the time to death, but actually
allowed many of the mice to survive until necropsy at
2 weeks. Likewise, anti-HMGB1 antibodies, given to mice
24 hours after cecal perforation, decreased mortality
compared with immunoglobin-G (IgG)-treated controls
(72% vs 28%; p < 0.03), and even “rescued” animals already
exhibiting signs of severe sepsis (Yang et al 2004). Ethyl
pyruvate, a nontoxic food derivative, blocks the effects of
HMGB1 by inhibiting its release from LPS- and TNF-
stimulated macrophages (Ulloa et al 2002). Treatment with
ethyl pyruvate conferred similar mortality and end-organ
damage protection even when given to mice 24 hours after
endotoxin challenge (Ulloa et al 2002).Vascular Health and Risk Management 2006:2(1) 14
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The HMGB1 protein has 3 distinct domains: 2 DNA
binding elements, called A-Box and B-box, and a negatively
charged C terminal. The cytokine activity of HMGB1
localizes to 20 amino acids found in the B-box DNA binding
domain (Li et al 2003). The A-box DNA binding site
competes with HMGB1 for binding sites on the surface of
macrophages and attenuates the release of TNF and IL-1
(Yang et al 2004). Administration of A-box peptide reduces
mortality in mice, even when administered up to 24 hours
after cecal ligation and puncture, providing further evidence
that HMGB1 antagonism may improve outcomes in sepsis.
The efficacy and safety of inhibiting HMGB1 in humans
with sepsis has not yet been demonstrated. However, the
encouraging results of HMGB1 inhibition in animal models,
combined with its “prolonged therapeutic window” have
brought enthusiasm for its use as a possible future
intervention for patients with severe sepsis or septic shock.
It remains unknown whether this inhibition is best
accomplished via antibodies, inhibitors like ethyl pyruvate,
or antagonists such as A-box peptide.
3-Hydroxy-3-methylglutaryl coenzyme
A reductase inhibitors (statins)
3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA)
reductase inhibitors, or statins, were originally developed
for reducing serum cholesterol levels. Subsequent
investigations demonstrated that they also reduced morbidity
and all-cause mortality in patients with cardio- or
cerebrovascular disease, including a reduction in non-
coronary mortality (Packard 1998). Research into the
mechanism for this benefit found that these medications
possess immunomodulatory effects independent of their
lipid lowering abilities.
As described above, endothelial dysfunction is a major
contributor to both the proinflammatory, procoagulant, and
antifibrinolytic cascades that occur in severe sepsis. Many
of the pleiotropic effects of statins are thought to be related
to their ability to prevent endothelial dysfunction and
enhance endothelial fibrinolytic and anticoagulant properties
(Takemoto and Liao 2001). Statins increase the expression
and enhance the activity of endothelial nitric oxide synthase
(eNOS) (Laufs et al 1998). Data also demonstrate that statins
restore eNOS activity in the presence of hypoxia (Laufs et
al 1997), which is often the condition of tissue capillaries
in septic shock. Endothelium-derived nitric oxide, produced
from eNOS, promotes vascular relaxation (Ignarro et al
1987), suppresses aggregation of platelets on the
endothelium (Radomski et al 1992), and inhibits endo-
thelium–leukocyte interactions (Kubes et al 1991). HMG-
CoA reductase inhibitors also possess other properties that
promote healthy endothelial function, including the ability
to upregulate tissue plasminogen activator (Essig et al 1998),
downregulate plasminogen activator inhibitor, decrease the
expression of TF (Aikawa et al 2001), and reduce oxidative
stress (Rikitake et al 2001). Additionally, statins reduce
vascular inflammation by reducing endothelial cell
expression of adhesion molecules, which further suppresses
the ability of leukocytes to attach to the endothelium
(Gauthier et al 1995; Niwa et al 1996).
Statins also possess antiinflammatory properties that may
prove beneficial in attenuating the inflammatory cascade
found in severe sepsis. Data demonstrate that HMG-CoA
reductase inhibitors impede the migration of inflammatory
cells (Dunzendorfer et al 1997) and inhibit neutrophil
chemotaxis (Kreuzer et al 1991). Furthermore, statins
suppress macrophage growth (Sakai et al 1997) and inhibit
the production and secretion of proinflammatory cytokines,
including TNF, IL-1, IL-6, and IL-8, from macrophages and
endothelial cells (Pahan et al 1997; Kothe et al 2000).
Animal data further suggest a role for statins in treating
severe sepsis. Mice, pretreated with intraperitoneal injection
of simvastatin (Merck and Co, Inc, Whitehouse Station, NJ,
USA) prior to induction of sepsis via a cecal ligation and
puncture model, lived 4 times as long as mice treated with
placebo (Merx et al 2004). This survival benefit occurred
despite similar rates of bacteremia. Pretreatment with
simvastatin preserved cardiac contractility as measured 20
hours after ligation and puncture, compared with a 28%
decline in cardiac output in control mice. Similarly,
leukocytes isolated from treated mice displayed a reduced
ability to adhere to cytokine-stimulated murine endothelial
cells compared with leukocytes harvested from control mice.
The same group of investigators has recently found similarly
encouraging results when HMG-CoA reductase inhibitors
are administered to mice after the onset of sepsis (Merx et
al 2005). In an identical model, mice treated with statins
lived twice as long as controls, despite not being treated
until 6 hours after cecal ligation and puncture. Delaying
treatment until after the manifestation of hemodynamic
alterations did not prevent treated mice from again
demonstrating preservation of cardiac function and
decreased leukocyte–endothelial adherence.
Although no randomized, controlled studies have
investigated the efficacy and safety of statins in treating
humans with severe sepsis or septic shock, retrospective andVascular Health and Risk Management 2006:2(1) 15
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observational data suggest a possible benefit. A retrospective
review of 388 cases of bacteremia from either aerobic gram-
negative rods or Staphylococcus aureus demonstrated a
reduction in both overall (6% vs 28%; p = 0.002) and
infectious mortality (3% vs 20%; p = 0.010) in patients
taking statins compared with those not taking statins (Liappis
et al 2001). A recent prospective observational cohort study
has found confirmatory data. This study evaluated 361
consecutive patients admitted to the hospital with presumed
or documented acute bacterial pneumonia (Almog et al
2004). Severe sepsis, or organ dysfunction attributable to
sepsis, developed in only 2.4% of patients who had been
treated with statins for longer than a month prior to
admission compared with 19% of patients not treated with
statins (p < 0.0001). Similarly, only 3.7% of patients treated
with statins required care in the ICU compared with 12.2%
of controls. Given these data, the relative risk of developing
severe sepsis associated with statin use was calculated to be
0.13 (95% CI: 0.03–0.52) and the relative risk of requiring
ICU care was 0.30 (95% CI: 0.1–0.95) (Almog et al 2004).
Unfortunately, the observational nature of both of these
studies yields significantly different baseline characteristics
between groups. Not unexpectedly, patients receiving statins
were more likely to be afflicted with hypertension, ischemic
heart disease, diabetes, and hyperlipidemia. However, they
also had significantly different sources of infection and were
less likely to demonstrate hypoalbuminemia or poly-
substance abuse (Liappis et al 2001; Almog et al 2004).
These differences in baseline characteristics and
uncontrolled administration of statins render cause and effect
determinations impossible. Large, multicenter, randomized,
blinded, placebo-controlled trials will need to be conducted
to effectively answer the question of whether or not treating
septic patients with statins improves clinical outcomes.
Conclusion
The complexity of medicine, including older patients with
greater comorbidities, more immunosuppression, and an
increasing use of invasive procedures, has resulted in a
dramatic rise in the incidence of severe sepsis and septic
shock. Despite the increasing burden on society, treatment
options remain limited. Drotrecogin alfa (activated) has
received regulatory approval for treatment of such patients,
but investigations continue in an attempt to optimize its
utilization. Replacement doses of corticosteroids and/or
vasopressin may also help in select subpopulations of
patients with septic shock.
The search for novel treatments has accelerated with the
emerging comprehension of the complex pathophysiology.
Animal data suggest that inhibiting late mediators of
inflammation, such as HMGB1, or mediators of both
inflammation and coagulation, like TF, may prove beneficial.
Uncontrolled studies in humans also suggest that HMG-
CoA reductase inhibitors, with their many pleiotropic
actions, may both prevent and attenuate the septic state.
Future investigations should continue to focus on improving
clinical outcomes, especially mortality, and may benefit
from a multifaceted approach of combining numerous agents
with different actions.
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